Glaukos Co. (NYSE:GKOS) COO Sells $11,587.80 in Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 105 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $110.36, for a total transaction of $11,587.80. Following the completion of the transaction, the chief operating officer now directly owns 101,845 shares in the company, valued at $11,239,614.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Glaukos Stock Down 1.0 %

Shares of Glaukos stock traded down $1.07 during trading on Wednesday, reaching $106.91. The company had a trading volume of 397,830 shares, compared to its average volume of 648,391. The company has a market cap of $5.38 billion, a price-to-earnings ratio of -37.12 and a beta of 1.08. The firm’s fifty day moving average is $93.94 and its 200-day moving average is $83.62. The company has a debt-to-equity ratio of 0.78, a quick ratio of 4.68 and a current ratio of 5.38. Glaukos Co. has a fifty-two week low of $54.38 and a fifty-two week high of $110.73.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). The company had revenue of $85.60 million during the quarter, compared to analyst estimates of $79.60 million. Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The business’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.59) EPS. On average, analysts anticipate that Glaukos Co. will post -2.2 EPS for the current year.

Institutional Investors Weigh In On Glaukos

Several institutional investors and hedge funds have recently bought and sold shares of the business. Xponance Inc. raised its stake in Glaukos by 4.1% during the fourth quarter. Xponance Inc. now owns 2,879 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 113 shares during the period. Valeo Financial Advisors LLC increased its stake in shares of Glaukos by 1.7% in the first quarter. Valeo Financial Advisors LLC now owns 8,932 shares of the medical instruments supplier’s stock valued at $902,000 after purchasing an additional 150 shares during the period. Corient Private Wealth LLC boosted its holdings in shares of Glaukos by 0.7% in the fourth quarter. Corient Private Wealth LLC now owns 24,775 shares of the medical instruments supplier’s stock valued at $1,969,000 after acquiring an additional 163 shares in the last quarter. Arizona State Retirement System boosted its holdings in Glaukos by 2.1% during the third quarter. Arizona State Retirement System now owns 13,040 shares of the medical instruments supplier’s stock worth $981,000 after buying an additional 264 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Glaukos by 17.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock worth $137,000 after purchasing an additional 270 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Truist Financial reissued a “buy” rating and issued a $125.00 price objective (up from $120.00) on shares of Glaukos in a research note on Thursday, May 2nd. Wells Fargo & Company raised their price target on shares of Glaukos from $103.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. Mizuho upped their target price on shares of Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 price target on shares of Glaukos in a research note on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $108.64.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.